GUT HEALTH DIGEST

UNIVERSITY OF WASHINGTON STRATEGIC ANALYSIS, RESEARCH & TRAINING (START) CENTER

REPORT TO THE BILL & MELINDA GATES FOUNDATION

OCTOBER 1, 2017

PRODUCED BY: KWIST, A; SLYKER J; ARNDT M;

Want the Gut Health Digest delivered directly to your inbox?
Subscribe on the Digest website: http://uwstartcenter.org/what-we-do/gut-health-digest/
<table>
<thead>
<tr>
<th>1.</th>
<th>Enteroaggregative E. coli Subclinical Infection and co-Infections and Impaired Child Growth in the MAL-ED Cohort Study.</th>
<th><a href="#">Abstract &amp; UW comment</a></th>
<th><a href="#">Full article</a></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Study investigating the impact of enteroaggregative Escherichia coli infection on child growth, when either alone or in combination with other pathogens.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Host-microbiota interactions and adaptive immunity.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • One review in a special series of reviews on the Microbiome-Immune System Interplay.

3. **Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Infants receiving a formula supplemented with commensal bacteria are compared with placebo and breastfed controls in this RCT to investigate changes in infant microbiome.

4. **Probiotics and the Gut Immune System: Indirect Regulation.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Review of the interplays between bacteria and host immunity with a focus on probiotics.

5. **Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Mouse model study investigating the ways in which the pre-existing microbial composition can modulate antibiotic treatment response.

6. **Deep Metaproteomics Approach for the Study of Human Microbiomes.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Analysis of the human microbiome from stool, combining high-resolution mass spectrometry and deep metaproteomics.

7. **Transmission of the gut microbiota: spreading of health.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Review of the transmission of human intestinal microbiota and its therapeutic potential.

8. **Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Mouse model study investigating impact of protein energy malnutrition on immunity and vaccine efficacy.

9. **Early Life Inflammation and Neurodevelopmental Outcome in Bangladeshi Infants Growing Up in Adversity.**  
   [Abstract & UW comment](#)  
   [Full article](#)  
   • Prospective cohort study of the relationship between systemic inflammation and poor neurodevelopment in children growing up in adversity.

10. **A randomized synbiotic trial to prevent sepsis among infants in rural India.**  
    [Abstract & UW comment](#)  
    [Full article](#)  
    • An RCT in India to test the effect of synbiotic treatment (probiotic and prebiotic combination) on the incidence of neonatal sepsis in term infants.
DETAILS OF ARTICLES

1. **Enteroaggregative E. coli Subclinical Infection and co-Infections and Impaired Child Growth in the MAL-ED Cohort Study.**

**ABSTRACT**

**OBJECTIVE:** We evaluated the impact of subclinical enteroaggregative Escherichia coli (EAEC) infection alone and in combination with other pathogens in the first six months of life on child growth.

**METHODS:** Non-diarrheal samples from 1,684 children across eight Multisite Birth Cohort Study, Malnutrition and Enteric Diseases (MAL-ED) sites in Asia, Africa, and Latin America were tested monthly; over 90% of children were followed-up twice weekly for the first six months of life.

**RESULTS:** Children with subclinical EAEC infection did not show altered growth between enrollment and six months. Conversely, EAEC co-infection with any other pathogen was negatively associated with delta weight-for-length (WLZ) \(p < 0.05\) and weight-for-age (WAZ) \(p > 0.05\) z-scores between 0 and 6 months. The presence of two or more pathogens without EAEC was not significantly associated with delta WLZ and WAZ. The most frequent EAEC co-infections included Campylobacter spp., heat-labile toxin-producing enterotoxigenic E. coli, Cryptosporidium spp., and atypical enteropathogenic E. coli. Myeloperoxidase levels were increased with EAEC co-infection \(p < 0.05\). EAEC pathogen co-detection was associated with lower neopterin levels compared to those of no-pathogen control children \(p < 0.05\). Mothers of children with EAEC co-infections had lower levels of education, poorer hygiene and sanitation, lower socioeconomic status, and lower breastfeeding rates compared to mothers of children in whom no pathogen was detected \(p < 0.05\).

**CONCLUSIONS:** These data emphasize the public health importance of subclinical EAEC infection in early infancy in association with other pathogens and the need for improved maternal and child care, hygiene, sanitation, and socioeconomic factors.

**WEB:** 10.1097/MPG.0000000000001717

**IMPACT FACTOR:** 1.48

**CITED HALF-LIFE:** 7.00

**START EDITORIAL COMMENT:** Investigators categorized the children into seven groups depending on presence of enteric pathogens: no pathogens detected, any EAEC detected, EAEC and one other pathogen, EAEC and two other pathogens, EAEC and three or more pathogens, one or two pathogens other than EAEC, three or more pathogens other than EAEC. By using this categorization, investigators were able to investigate the true impact of EAEC alone versus a possible synergistic effect of multiple pathogens. Figure 4 provides WAZ, WLZ, and LAZ z-scores for all seven groups, showing that EAEC infection was only associated with impaired child growth in the case of co-infection with another pathogen. The EAEC and co-infection with 2-3 pathogens group was associated with higher fecal Myeloperoxidase concentrations, which may suggest synergy between EAEC and other pathogens on elicitation of neutrophil-mediated immune responses.

2. **Host-microbiota interactions and adaptive immunity.**
   McCoy K, Ronchi F, Geuking M.

**ABSTRACT**
The mammalian intestine is densely populated by non-pathogenic (commensal) microbes, which reach a density of 10^{12} CFU/g of colonic luminal content. The commensal microbiota is of crucial importance for the host as it plays a role in shaping the immune system, inducing protective immune responses, providing the host with essential nutrients and vitamins, aiding in the digestion of indigestible food components, and competing with pathogens for the same niches.1 The mucosal epithelium mounts multiple innate immune mechanisms that function at mucosal sites to promote barrier function and maintain host-microbial homeostasis.2 The resident intestinal microbiota also induces robust adaptive immunity that includes induction and differentiation of CD4+ T cells, intestinal epithelial lymphocytes (IEL), and B cells.3 In this review, we will discuss recent developments in the interplay between the intestinal microbiota and the adaptive immune system, with particular focus on the induction of systemic anti-microbial IgG responses, the function of microbial-induced maternal antibodies, and microbial-specific T-cell immunity.

WEB: 10.1111/imr.12575
IMPACT FACTOR: 15.33
CITED HALF-LIFE: 6.20

START EDITORIAL COMMENT: This month, Immunological Reviews published a special issue on Microbiome-Immune System Interplay. The issue includes several reviews relevant to this digest—while all cannot be included here due to limited space and diversity of articles, it might be worth reviewing for those interested in how the microbiome influences host immunity. This review covers mouse models of the role mucosal microbiota play in the induction of dominant IgA and IgG antibodies such as commensal bacteria-specific responses, maternal-infant transfer of antibodies (i.e. secretory IgA) and prevention of translocation into the mesenteric lymph nodes, CD4+ T-cell interplay, and the inhibition of IgE overexpression.

3. Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome.

ABSTRACT
BACKGROUND: Early-life colonization of the intestinal tract is a dynamic process influenced by numerous factors. The impact of probiotic-supplemented infant formula on the composition and function of the infant gut microbiota is not well defined.
OBJECTIVE: We sought to determine the effects of a bifidobacteria-containing formula on the healthy human intestinal microbiome during the first year of life.
DESIGN: A double-blind, randomized, placebo-controlled study of newborn infants assigned to a standard whey-based formula containing a total of 10^8 colony-forming units (CFU)/g of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, B. longum subspecies infantis (intervention), or to a control formula without bifidobacteria (placebo). Breastfed controls were included. Diversity and composition of fecal microbiota were determined by 16S ribosomal RNA gene amplicon sequencing, and metabolite profiles were analyzed by ultrahigh-performance liquid chromatography-mass spectrometry over a period of 2 y.
RESULTS: Infants (n = 106) were randomly assigned to either the interventional (n = 48) or placebo (n = 49) group; 9 infants were exclusively breastfed throughout the entire intervention period of 12 mo. Infants exposed to bifidobacteria-supplemented formula showed decreased occurrence of Bacteroides and Blautia spp. associated with changes in lipids and unknown metabolites at month 1.
Microbiota and metabolite profiles of intervention and placebo groups converged during the study period, and long-term colonization (24 mo) of the supplemented Bifidobacterium strains was not detected. Significant differences in microbiota and metabolites were detected between infants fed breast milk and those fed formula (P < 0.005) and between infants birthed vaginally and those birthed by cesarean delivery (P < 0.005). No significant differences were observed between infant feeding groups regarding growth, antibiotic uptake, or other health variables (P > 0.05).

CONCLUSION: The supplementation of bifidobacteria to infant diet can modulate the occurrence of specific bacteria and metabolites during early life with no detectable long-term effects.

WEB: 10.3945/ajcn.117.157529
IMPACT FACTOR: 4.56
CITED HALF-LIFE: 9.60

START EDITORIAL COMMENT: Over the 12 months of the study, differences in the sequence abundance of major bacterial phyla converged in the 3 groups. By 24 months, none of the 4 strains included in the bifido-supplemented formula were detected in any of the arms. This suggests transient differences between bifido-supplemented infants and non-supplemented infants. Also, infants with formula with and without bifido supplements were more similar in terms of the richness and diversity of their microbiome than those in breastfed group, and their metabolic profiles were more similar as well (figure 5D). Figure 3 presents visual representations of microbiota changes throughout the first year of life in each of the three study arms. Panel C of Figure 3 presents relative abundances of Actinobacteria, Firmicutes, Bacteroidetes, and Proteobacteria. It can be seen in this panel that the relative abundances among the different study arms differ greatly for each bacteria – for example, the relative abundance of Actinobacteria is much higher in breastfed infants, while the relative of Firmicutes is much lower in breastfed infants. One limitation is that the breastfed group was much smaller than the other two formula-fed groups.

La Fata G, Weber P, Mohajeri M.

ABSTRACT
The gastrointestinal tract (GIT) represents the largest interface between the human organism and the external environment. In the lumen and upper part of the mucus layer, this organ hosts an enormous number of microorganisms whose composition affects the functions of the epithelial barrier and the gut immune system. Consequently, the microorganisms in the GIT influence the health status of the organism. Probiotics are living microorganisms which, in specific conditions, confer a health benefit to the host. Among others, probiotics have immunomodulatory properties that usually act directly by (a) increasing the activity of macrophages or natural killer cells, (b) modulating the secretion of immunoglobulins or cytokines, or indirectly by (c) enhancing the gut epithelial barrier, (d) altering the mucus secretion, and (e) competitive exclusion of other (pathogenic) bacteria. This review focuses on specific bacteria strains with indirect immunomodulatory properties. Particularly, we describe here the mechanisms through which specific probiotics enhance the gut epithelial barrier and modulate mucus production. Moreover, we describe the antimicrobial properties of specific bacteria strains. Recent data suggest that multiple pathologies are associated with an unbalanced gut microflora (dysbiosis). Although the cause-effect relationship between pathology and gut microflora is not yet well established, consumption of specific probiotics may represent a powerful tool to reestablish gut homeostasis and promote gut health.
START EDITORIAL COMMENT: After broadly introducing microbiota and probiotics, the article reviews three main interplays between bacteria and host immunity: probiotics’ effect on the gut epithelial barrier, mucus secretion and modulation, and various antimicrobial properties of beneficial and pathogenic bacteria. Authors also provide a detailed description of the makeup and function of the gut intestinal barrier in order to better inform the above three sections. Figure 1 is a visual representation of the intestinal barrier, which shows the location and function of various cell types and gut bacteria, in addition to displaying several interactions between bacteria and intestinal barrier. Tables 1, 2, 3 describe evidence supporting probiotic strains’ improvement of intestinal epithelial function, regulation of the mucous layer, and antimicrobial properties, respectively.

5. Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.

ABSTRACT
Antibiotics are important for treating bacterial infection; however, efficacies and side effects of antibiotics vary in medicine and experimental models. A few studies have correlated microbiota composition variations with health outcomes in response to antibiotics; however, no study has demonstrated causality. We had noted variation in colonic expression of C-type lectins, regenerating islet-derived protein 3β (Reg3β) and Reg3γ, after metronidazole treatment in a mouse model. To investigate the effects of specific variations in the preexisting microbiome on host response to antibiotics, mice harboring a normal microbiota were allocated to 4 treatments in a 2-by-2 factorial arrangement with or without commensal Escherichia coli and with or without metronidazole in drinking water. E. coli colonized readily without causing a notable shift in the microbiota or host response. Metronidazole administration reduced microbiota biodiversity, indicated by decreased Chao1 and Shannon index values, and altered microbiota composition. However, the presence of E. coli strongly affected metronidazole-induced microbiota shifts. Remarkably, this single commensal bacterium in the context of a complex population led to variations in host responses to metronidazole treatment, including increased expression of antimicrobial peptides Reg3β and Reg3γ and intestinal inflammation indicated by tumor necrosis factor alpha levels. Similar results were obtained from 2-week antibiotic exposure and with additional E. coli isolates. The results of this proof-of-concept study indicate that even minor variations in initial commensal microbiota can drive shifts in microbial composition and host response after antibiotic administration. As well as providing an explanation for variability in animal models using antibiotics, the findings encourage the development of personalized medication in antibiotic therapies.

IMPORTANCE: This work provides an understanding of variability in studies where antibiotics are used to alter the gut microbiota to generate a host response. Furthermore, although providing evidence only for the one antibiotic, the study demonstrated that initial gut microbial composition is a key factor driving host response to antibiotic administration, creating a compelling argument for considering personalized medication based on individual variations in gut microbiota.

WEB: 10.1128/AEM.01107-17
START EDITORIAL COMMENT: Treatment of mice with a commensal E. coli strain altered the relationship between administration of metronidazole and expression of antimicrobial peptides and inflammation. This may have ramifications for treatment in humans, so further research is needed. While this study provides important insight into initial microbial composition as a determinant of antibiotic response, it uses only one specific broad-spectrum antibiotic to do so. Additionally, this particular antibiotic, metronidazole, may have other indirect effects on the microbiome in light of its anti-parasitic activity.

6. **Deep Metaproteomics Approach for the Study of Human Microbiomes.**
   Zhang X, Chen W, Ning Z, Mayne J, Mack D, Stintzi A.

ABSTRACT
Host–microbiome interactions have been shown to play important roles in human health and diseases. Most of the current studies of the microbiome have been performed by genomic approaches through next-generation sequencing. Technologies, such as metaproteomics, for functional analysis of the microbiome are needed to better understand the intricate host–microbiome interactions. However, significant efforts to improve the depth and resolution of gut metaproteomics are still required. In this study, we combined an efficient sample preparation technique, high resolution mass spectrometry, and metaproteomic bioinformatics tools to perform ultradeep metaproteomic analysis of human gut microbiome from stool. We reported the deepest analysis of the microbiome to date with an average of 20558 protein groups identified per sample analysis. Moreover, strain resolution taxonomic and pathway analysis using deep metaproteomics revealed strain level variations, in particular for Faecalibacterium prausnitzii, in the microbiome from the different individuals. We also reported that the human proteins identified in stool samples are functionally enriched in extracellular region pathways and in particular those proteins involved in defense response against microbial organisms. Deep metaproteomics is a promising approach to perform in-depth microbiome analysis and simultaneously reveals both human and microbial changes that are not readily apparent using the standard genomic approaches.

WEB: [10.1021/acsnano.7b02224](http://dx.doi.org/10.1021/acsnano.7b02224)

START EDITORIAL COMMENT: Figure 3 gives a visual representation of the potential of deep metaproteomics by presenting the taxonomic analysis described in the article’s abstract above. This includes strain-level analysis of abundant species of microbiota among the entire data set, strain-level distributions, and relative abundance, of three of the most abundant species: F. prausnitzii, B. thetaiotaomicron, and E. rectale. Authors note that one particular benefit of this approach is that deep metaproteomics allows analysis of human proteins in addition to microbiota proteins, which might provide a way to further study host-microbe interactions. Table 1 gives a breakdown of 35 of the most abundant human proteins that were analyzed for association with the microbiome, of which nearly all were significantly associated. Limitations include a small number of children in the study (n=4) and no description of their ages; however, the study accomplishes its primary goal of being a proof of concept for the application of this new technology.
Browne HP, Neville BA, Forster SC, Lawley TD.

ABSTRACT
Transmission of commensal intestinal bacteria between humans could promote health by establishing, maintaining and replenishing microbial diversity in the microbiota of an individual. Unlike pathogens, the routes of transmission for commensal bacteria remain unappreciated and poorly understood, despite the likely commonalities between both. Consequently, broad infection control measures that are designed to prevent pathogen transmission and infection, such as over sanitation and the overuse of antibiotics, may inadvertently affect human health by altering normal commensal transmission. In this Review, we discuss the mechanisms and factors that influence host-to-host transmission of the intestinal microbiota and examine how a better understanding of these processes will identify new approaches to nurture and restore transmission routes that are used by beneficial bacteria.

WEB: 10.1038/nrmicro.2017.50
IMPACT FACTOR: 9.76
CITED HALF-LIFE: 5.80

START EDITORIAL COMMENT: This review takes a comprehensive and holistic approach in discussing the transmission of human intestinal microbiota. Topics discussed include the various shared and distinguished transmission routes between commensal and pathogenic bacteria, host selection of commensal bacteria, microbiota survival in the environment, common reservoirs of commensal bacteria, and finally microbiota perturbation and restoration. Of particular interest is the last section, in which authors discuss the various ways in which microbiota diversity can be negatively impacted— including poor diet and overuse of antibiotics— and discuss recent developments in interventions to counter these impairments. Pre-incubated neonatal swabs, faecal microbiota transplantation (FMT), and probiotics are among the interventions discussed. FMT is highlighted as a very successful method for treatment of recurrent C. difficile infection recently and authors hypothesize that biotherapeutics will soon offer treatments for other similar disorders. Figure 4 highlights donor suitability for commensal microbiota donation based upon signature species, microbiota features, and bacterial profile. Authors emphasize the importance of building the evidence base for the health benefits of individual members of commensal bacterial communities.

8. Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice.

ABSTRACT
Oral vaccine responsiveness is often lower in children from less developed countries. Childhood malnutrition may be associated with poor immune response to oral vaccines. The present study was designed to investigate whether protein energy malnutrition (PEM) impairs B cell immunity and ultimately reduces oral vaccine efficacy in a mouse model. Purified isocaloric diets containing low protein (1/10 the protein of the control diet) were used to determine the effect of PEM. PEM increased
both nonspecific total IgA and oral antigen-specific IgA in serum without alteration of gut permeability. However, PEM decreased oral antigen-specific IgA in feces, which is consistent with decreased expression of polymeric Immunoglobulin receptor (pIgR) in the small intestine. Of note, polymeric IgA was predominant in serum under PEM. In addition, PEM altered B cell development status in the bone marrow and increased the frequency of IgA-secreting B cells, as well as IgA secretion by long-lived plasma cells in the small intestinal lamina propria. Moreover, PEM reduced the protective efficacy of the mucosally administered cholera vaccine and recombinant attenuated Salmonella enterica serovar Typhimurium vaccine in a mouse model. Our results suggest that PEM can impair mucosal immunity where IgA plays an important role in host protection and may partly explain the reduced efficacy of oral vaccines in malnourished subjects.

WEB: 10.1016/j.imlet.2017.08.025
IMPACT FACTOR: 1.85
CITED HALF-LIFE: 7.70

START EDITORIAL COMMENT: Figure 1 provides five informative and intuitive visual representations of the results of this study, including an analysis of various immunoglobulin subgroups between study arms, a comparison of IgA and IgG between study arms stratified by serum vs. feces analysis, and an in vivo permeability analysis to assess intestinal barrier function. Interestingly, there were marked decreases in IgA but not IgG in protein energy malnourished (PEM) mice. Also, there was lower S. typhimurium-specific IgA in the feces of PEM mice, but higher IgA in serum of PEM mice, compared with mice receiving normal nutrition. One limitation of this study is the use of fecal biomarker concentrations as a proxy for the analysis of the local IgA levels in portions of the intestinal tract. While challenging or unfeasible in human populations living in low resource settings (especially in children), sacrifice and duodenal and ileal biopsy would have yielded richer data in these murine models. A second limitation is lack of survival analyses for S. Typhimurium and cholera vaccine challenge models, a missed opportunity for understanding the different survival experiences of the two groups.


ABSTRACT
Exposure to profound adversity can negatively affect the neurodevelopment of children, but biologic mechanisms that underlie this association remain unknown. We sought to determine whether elevated levels of the inflammatory markers C-reactive protein (CRP) and soluble CD14 (sCD14) are associated with neurodevelopmental outcomes in Bangladeshi children. A total of 422 infant-mother pairs from an urban slum in Dhaka, Bangladesh, were enrolled at birth and followed prospectively. Inflammation was measured with sCD14, interleukin (IL)-1β, and IL-6 at 18 weeks, and CRP at 6, 18, 40, and 53 weeks. Psychologists assessed cognitive, language, motor, and social emotional development using the Bayley Scales of Infant and Toddler Development at 78 and 104 weeks of age. We tested for the association of inflammatory markers with developmental outcomes, independent of previously identified associations such as malnutrition, family income, and maternal education. Every 10 pg/mL increase in sCD14 was associated with a 1.1-2.0 decrement in cognitive and motor scores at 78 weeks and in all domains at 104 weeks. The cumulative number of CRP elevations that a child experienced in the first year of life, as well as IL-1β and IL-6 at 18 weeks of age, were also negatively associated with Bayley Scales results. CRP,
sCD14, IL-1β, and IL-6 were associated with lower neurodevelopmental outcomes. Our findings implicate a role of inflammation in the neurodevelopment of children growing up in adversity.

WEB: 10.4269/ajtmh.17-0083
IMPACT FACTOR: 1.67
CITED HALF-LIFE: 9.80

START EDITORIAL COMMENT: Two main points are of note in this study of rural Bangladeshi infants enrolled in the cohort. First, plasma sCD14 concentrations at age 18 weeks, a marker of monocyte activation primarily attributable translocation of gram-negative (LPS-containing) bacterial species, was negatively associated with cognitive, socio-emotional, and motor scores at age 2 years. Because sCD14 has previously been associated with linear growth faltering and oral vaccine efficacy (Naylor et al. 2015 and Guerrant 2016), this association presents an important area for further research and this study helps to contribute to the growing body of knowledge for the mechanistic links between cognition and inflammation. Additionally, it presents an area for possible inflammation therapy through this pathway. Second, building upon prior observations of associations between child growth and levels of systemic inflammation marker CRP (Prendergast 2014- Zimbabwe, among others)- there was a dose-response relationship observed between CRP assessed at multiple time points and neurodevelopmental outcomes at age 2 years, with worse outcomes as the levels of CRP increased. Interestingly, because CRP is an acute-phase protein, the repeated assessment of this marker enabled the authors to treat each elevation in CRP as an inflammatory “hit”, with hits accumulating over early life. While CRP is not a source-specific signal of systemic inflammation, microbial translocation represents one major source of such hits.

10. A randomized synbiotic trial to prevent sepsis among infants in rural India.

ABSTRACT
Sepsis in early infancy results in one million annual deaths worldwide, most of them in developing countries. No efficient means of prevention is currently available. Here we report on a randomized, double-blind, placebo-controlled trial of an oral synbiotic preparation (Lactobacillus plantarum plus fructooligosaccharide) in rural Indian newborns. We enrolled 4,556 infants that were at least 2,000 g at birth, at least 35 weeks of gestation, and with no signs of sepsis or other morbidity, and monitored them for 60 days. We show a significant reduction in the primary outcome (combination of sepsis and death) in the treatment arm (risk ratio 0.60, 95% confidence interval 0.48-0.74), with few deaths (4 placebo, 6 synbiotic). Significant reductions were also observed for culture-positive and culture-negative sepsis and lower respiratory tract infections. These findings suggest that a large proportion of neonatal sepsis in developing countries could be effectively prevented using a synbiotic containing L. plantarum ATCC-202195.

WEB: 10.1038/nature23480
IMPACT FACTOR: 11.57
CITED HALF-LIFE: N/A

START EDITORIAL COMMENT: This study contributes to the growing knowledge around the efficacy of synbiotic (probiotic + prebiotic) therapy for the prevention of a number of common diseases, which has had mixed results in prior studies. In this study, investigators saw a 40% reduction in the primary
outcome of sepsis and death in the treatment group of more than 2,000 infants, who received the symbiotic compared with the placebo group. Table 2 provides counts and relative risk measures for this primary outcome, in addition to secondary outcomes including the all-cause diarrhea (RR= 0.20), lower respiratory tract infections (RR= 0.66), and omphalitis (RR= 0.23). Impressively, the number needed to treat for the primary outcome was only 27. As the therapy costs an estimated $1 per child, a $27 investment in the therapy would result in one less case of sepsis in this population. Authors stressed the importance of further research comparing the timing of intervention, the need to test therapy in preterm/underweight infants who are at increased risk for fatal sepsis, and the specific choice of probiotic used (as this may differ in other settings and/or high-risk groups).

ADDITIONAL ARTICLES OF INTEREST

The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Targeting the gut microbiota by dietary nutrients: a new avenue for human health.

Gut Protozoa: Friends or Foes of the Human Gut Microbiota?

Fecal Microbiota Transplantation: Beyond Clostridium difficile.

ARTICLE ARCHIVE (JAN 2016-PRESENT)

EED Biology & Review Articles

The regulation of gut mucosal IgA B-cell responses: recent developments.

Infant Nutritional Status and Markers of Environmental Enteric Dysfunction are Associated with Midchildhood Anthropometry and Blood Pressure in Tanzania.

The Burden of Enteropathy and "Subclinical" Infections.

Introducing the sporobiota and sporobiome.

Patterns of Early-Life Gut Microbial Colonization during Human Immune Development: An Ecological Perspective

Parasitic protozoa and interactions with the host intestinal microbiota.

Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice.

New insights into environmental enteric dysfunction.

Tropical Enteropathies.

Age and Sex Normalization of Intestinal Permeability Measures for the Improved Assessment of Enteropathy in Infancy and Early Childhood: Results from the MAL-ED Study.
Infant Nutritional Status and Markers of Environmental Enteric Dysfunction are Associated with Midchildhood Anthropometry and Blood Pressure in Tanzania.

Biomarkers to Stratify Risk Groups among Children with Malnutrition in Resource-Limited Settings and to Monitor Response to Intervention

Association between Enteropathogens and Malnutrition in Children Aged 6-23 mo in Bangladesh: a Case-Control Study.

Causal Pathways from Enteropathogens to Environmental Enteropathy: Findings from the MAL-ED Birth Cohort Study.

Biomarkers of Environmental Enteric Dysfunction: The good, the bad and the ugly.

Application of penalized linear regression methods to the selection of environmental enteropathy biomarkers.

Environmental enteropathy is associated with cardiometabolic risk factors in Peruvian children.

Biomarkers of Environmental Enteric Dysfunction Among Children in Rural Bangladesh.

Environmental Enteric Dysfunction is Associated with Carnitine Deficiency and Altered Fatty Acid Oxidation.

Determinant Variables, Enteric Pathogen Burden, Gut Function, and Immune-Related Inflammatory Biomarkers Associated with Childhood Malnutrition: A Prospective Case-Control Study in Northeastern Brazil.

The Association Between Fecal Biomarkers of Environmental Enteropathy and Rotavirus Vaccine Response in Nicaraguan Infants.

Systemic inflammation, growth factors, and linear growth in the setting of infection and malnutrition.

Environmental Enteric Dysfunction and the Fecal Microbiota in Malawian Children

Environmental Enteric Dysfunction and Growth Failure/Stunting in Global Child Health

Biomarkers of Environmental Enteropathy, Inflammation, Stunting, and Impaired Growth in Children in Northeast Brazil.

Environmental enteropathy.

Environmental Enteropathy: Elusive but Significant Subclinical Abnormalities in Developing Countries.

Endomicroscopic and Transcriptomic Analysis of Impaired Barrier Function and Malabsorption in Environmental

Environmental Enteric Dysfunction in Children.
Environmental Enteric Dysfunction Includes a Broad Spectrum of Inflammatory Responses and Epithelial Repair Processes.

The Impact of Environmental Enteropathy and Systemic Inflammation on Infant Growth Failure

Small Intestine Bacterial Overgrowth and Environmental Enteropathy in Bangladeshi Children.

Decoding Hidden Messages: Can Fecal Host Transcriptomics Open Pathways to Understanding Environmental Enteropathy?

Plasma Tryptophan and the Kynurenine–Tryptophan Ratio are Associated with the Acquisition of Statural Growth Deficits and Oral Vaccine Underperformance in Populations with Environmental Enteropathy

Malnutrition Is Associated with Protection from Rotavirus Diarrhea: Evidence from a Longitudinal Birth Cohort Study in Bangladesh

Nutrition/metabolism

Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants.

Cross-modulation of pathogen-specific pathways enhances malnutrition during enteric co-infection with Giardia lamblia and enteroaggregative Escherichia coli.

Impaired Barrier Function and Autoantibody Generation in Malnutrition Enteropathy in Zambia.

Formula diet driven microbiota shifts tryptophan metabolism from serotonin to tryptamine in neonatal porcine colon.

Detrimental Impact of Microbiota-Accessible Carbohydrate-Deprived Diet on Gut and Immune Homeostasis: An Overview

Chronic consequences on human health induced by microbial pathogens: Growth faltering among children in developing countries.

The effects of micronutrient deficiencies on bacterial species from the human gut microbiota.

Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals.

The association of serum choline with linear growth failure in young children from rural Malawi.

Starved Guts: Morphologic and Functional Intestinal Changes in Malnutrition.

Which dietary components modulate longitudinal growth?

Influence of diet on the gut microbiome and implications for human health.
Nopal feeding reduces adiposity, intestinal inflammation and shifts the cecal microbiota and metabolism in high-fat fed rats.

Western diets, gut dysbiosis, and metabolic diseases: Are they linked?

Nutrition, infection and stunting: the roles of deficiencies of individual nutrients and foods, and of inflammation, as determinants of reduced linear growth of children.

Microbiome, Growth Retardation, and Metabolism: Are they related?

Linking Dietary Patterns with Gut Microbial Composition and Function.

Impacts of resistant starch and wheat bran consumption on enteric inflammation in relation to colonic bacterial community structures and short-chain fatty acid concentrations in mice.

Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues.

Systemic inflammation, growth factors, and linear growth in the setting of infection and malnutrition.

Environmental Enteric Dysfunction is Associated with Altered Bile Acid Metabolism.

Metabolic alterations in children with environmental enteric dysfunction.

Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.

Interactions between intestinal pathogens, enteropathy and malnutrition in developing countries.

Child Stunting is Associated with Low Circulating Essential Amino Acids.

Diet–microbiota interactions as moderators of human metabolism.

Protein malnutrition impairs intestinal epithelial turnover: a potential mechanism of increased cryptosporidiosis in a murine model.

A Comparison of Diarrheal Severity Scores in the MAL-ED Multisite Community-Based Cohort Study.

Metabolomic Changes in Serum of Children with Different Clinical Diagnoses of Malnutrition.

Mortality in children with complicated severe acute malnutrition is related to intestinal and systemic inflammation: an observational cohort study.

Steroid Administration and Growth Impairment in Children with Crohn's Disease.

Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutrition.
A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility

Microbiome Therapies

A benign helminth alters the host immune system and the gut microbiota in a rat model system.

Lactobacillus acidophilus/Bifidobacterium infantis probiotics are associated with increased growth of VLBWI among those exposed to antibiotics.

Early antibiotic exposure in low-resource settings is associated with increased weight in the first two years of life.

The path towards microbiome-based metabolite treatment.

Next-generation probiotics: the spectrum from probiotics to live biotherapeutics

Severity of pancreatitis-associated intestinal mucosal barrier injury is reduced following treatment with the NADPH oxidase inhibitor apocynin.

Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction.

Interleukin-23 Increases Intestinal Epithelial Cell Permeability In Vitro

Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function.

The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation

Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice

Longitudinal change of selected human milk oligosaccharides and association to infants' growth, an observatory, single center, longitudinal cohort study

Abrupt suspension of probiotics administration may increase host pathogen susceptibility by inducing gut dysbiosis

Toward a Personalized Approach in Prebiotics Research

Dietary Fiber and Prebiotics and the Gastrointestinal Microbiota.

A microbial protein that alleviates metabolic syndrome

Can probiotics modulate human disease by impacting intestinal barrier function?

Human Milk Oligosaccharides Influence Neonatal Mucosal and Systemic Immunity.

Oral Microbiota in Infants Fed a Formula Supplemented with Bovine Milk Fat Globule Membranes - A Randomized Controlled Trial.
Dietary Prebiotics and Bioactive Milk Fractions Improve NREM Sleep, Enhance REM Sleep Rebound and Attenuate the Stress-Induced Decrease in Diurnal Temperature and Gut Microbial Alpha Diversity.

Impact of prebiotics on metabolic and behavioral alterations in a mouse model of metabolic syndrome.

Starter formula enriched in prebiotics and probiotics ensures normal growth of infants and promotes gut health: a randomized clinical trial.

Diet-induced extinctions in the gut microbiota compound over generations

Microbiome: Eating for trillions

An important chapter in the infection-malnutrition story.

Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition

Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children

Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition

Effects of bovine colostrum on recurrent respiratory tract infections and diarrhea in children.

Sialylated galacto-oligosaccharides and 2'-fucosyllactose reduce necrotising enterocolitis in neonatal rats

Rebooting the microbiome.

Fecal microbiota transplantation: in perspective.

Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity

Microbial therapeutic interventions.

High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice

Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome

Protein- and zinc-deficient diets modulate the murine microbiome and metabolic phenotype

Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity

Overcoming the limited availability of human milk oligosaccharides: challenges and opportunities for research and application
Efficacy of Probiotics Versus Placebo in the Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double-Blind Randomized Controlled Trial

Eosinophils, probiotics, and the microbiome.

A Combined Intervention of Zinc, Multiple Micronutrients, and Albendazole Does Not Ameliorate Environmental Enteric Dysfunction or Stunting in Rural Malawian Children in a Double-Blind Randomized Controlled Trial

Gut Health Diagnostics & Research

The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability.

Genome-resolved metaproteomic characterization of preterm infant gut microbiota development reveals species-specific metabolic shifts and variabilities during early life.

More than just a gut feeling: constraint-based genome-scale metabolic models for predicting functions of human intestinal microbes.

Potential and active functions in the gut microbiota of a healthy human cohort.

Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43.

Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene.

Organs-on-chips with integrated electrodes for trans-epithelial electrical resistance (TEER) measurements of human epithelial barrier function.

A methodologic framework for modeling and assessing biomarkers of environmental enteropathy as predictors of growth in infants: an example from a Peruvian birth cohort.

Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation.

Engineered Regulatory Systems Modulate Gene Expression of Human Commensals in the Gut

MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data.

Honeybee gut microbiota promotes host weight gain via bacterial metabolism and hormonal signaling.

Leading microbiome-based therapeutic falters in Phase II trial

Faecal microbiota transplantation—A clinical view.

Optimization of metabolomics of defined in vitro gut microbial ecosystems
Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota.

Challenges of metabolomics in human gut microbiota research

The Role of the Immune System in Metabolic Health and Disease

Optimization of metabolomics of defined in vitro gut microbial ecosystems.

An Intestinal Organ Culture System Uncovers a Role for the Nervous System in Microbe-Immune Crosstalks.

Droplet digital PCR quantifies host inflammatory transcripts in feces reliably and reproducibly.

Gut-Brain Cross-Talk in Metabolic Control

Dynamics of the human microbiome in inflammatory bowel disease

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

Tryptophan: A gut microbiota-derived metabolites regulating inflammation

Dynamics and Trends in Fecal Biomarkers of Gut Function in Children from 1-24 Months in the MAL-ED Study.

Fecal Markers of Environmental Enteropathy and Subsequent Growth in Bangladeshi Children.

Etiology of Diarrhea, Nutritional Outcomes and Novel Intestinal Biomarkers in Tanzanian Infants: A Preliminary Study.

Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device.

MiniBioReactor Arrays (MBRAs) as a Tool for Studying C. difficile Physiology in the Presence of a Complex Community.

Reverse Engineering Human Pathophysiology with Organs-on-Chips.

Human Microbiota-Associated Mice: A Model with Challenges

Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip.

Optimization of Quantitative PCR Methods for Enteropathogen Detection

Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study
Diagnostics: Filling in the missing pieces

Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability

Gut check

Population-level analysis of gut microbiome variation

Childhood undernutrition, the gut microbiota, and microbiota-directed therapeutics

Environmental Enteric Dysfunction is Associated with Poor Linear Growth and Can be Identified by Host Fecal mRNAs

Commendation for Exposing Key Advantage of Organ Chip Approach

Biomarkers of Environmental Enteropathy are Positively Associated with Immune Responses to an Oral Cholera Vaccine in Bangladeshi Children

Shifts in *Lachnospira* and *Clostridium* sp. in the 3-month stool microbiome are associated with preschool age asthma

Other Gut Infections/Health

Longitudinal development of the gut microbiome and metabolome in preterm neonates with late onset sepsis and healthy controls.

(Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease.

Chemical and pathogen-induced inflammation disrupt the murine intestinal microbiome.

Transient activation of mucosal effector immune responses by resident intestinal bacteria in normal hosts is regulated by interleukin-10 signalling.

Zinc Transporter SLC39A7/ZIP7 Promotes Intestinal Epithelial Self-Renewal by Resolving ER Stress.

Regulation of intestinal permeability: the role of proteases.

Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments

Bap180/Baf180 is required to maintain homeostasis of intestinal innate immune response in *Drosophila* and mice

Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction
Mice with infectious colitis exhibit linear growth failure and subsequent catch-up growth related to systemic inflammation and IGF-1.

Molecular insight into Evolution of Symbiosis between Breast-Fed Infants and a Member of the Human Gut Microbiome Bifidobacterium longum

An insider’s perspective: Bacteroides as a window into the microbiome

Antibiotics, Pediatric Dysbiosis, and Disease

Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance.

Host cell attachment elicits posttranscriptional regulation in infecting enteropathogenic bacteria.

Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis.

A prominent glycyl radical enzyme in human gut microbiomes metabolizes trans-4-hydroxy-l-proline.

The Bactericidal Lectin RegIIIβ Prolongs Gut Colonization and Enteropathy in the Streptomycin Mouse Model for Salmonella Diarrhea.

Mining the Human Gut Microbiota for Immunomodulatory Organisms.

Feedback control of AHR signalling regulates intestinal immunity

Reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects: A randomized controlled trial: Arabinoxylans in gut barrier.

Changes in Intestinal Motility and Gut Microbiota Composition in a Rat Stress Model

Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens.

Intestinal commensal bacteria mediate lunch mucosal immunity and promote resistance of newborn mice to infection.

Statoviruses, A novel taxon of RNA viruses present in the gastrointestinal tracts of diverse mammals.

Campylobacter jejuni and associated immune mechanisms: short-term effects and long-term implications for infants in low-income countries.

The Role of Fibronectin in the Adherence and Inflammatory Response Induced by Enteroaggregative Escherichia coli on Epithelial Cells.

Early-life enteric infections: relation between chronic systemic inflammation and poor cognition in children.

GEMS extend understanding of childhood diarrhoea
Infectious disease: something in the water

Genomic diversity of EPEC associated with clinical presentations of differing severity. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease

Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease

Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome

Giardia: a pathogen or commensal for children in high-prevalence settings?

Tuft Cells: New Players in Colitis.

PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells

Dysbiosis is not an answer

Epidemiology and Impact of Campylobacter Infection in Children in 8 Low-Resource Settings: Results From the MAL-ED Study

The microbiota and immune response during Clostridium difficile infection

Enterocyte Purge and Rapid Recovery Is a Resilience Reaction of the Gut Epithelium to Pore-Forming Toxin Attack

Microbiome & Infection

Epidemiology of enteroaggregative Escherichia coli infections and associated outcomes in the MAL-ED birth cohort.

Antigen-specific regulatory T-cell responses to intestinal microbiota.

The Gut Microbiome: Connecting Spatial Organization to Function

Intestinal, extra-intestinal and systemic sequelae of Toxoplasma gondii induced acute ileitis in mice harboring a human gut microbiota.

The shape of the microbiome in early life

Dysbiosis and the immune system.

Dysbiosis in intestinal inflammation: Cause or consequence

Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice

Microbiome-Modulated metabolites at the Interface of Host Immunity

Gastrointestinal Inflammation and Repair: Role of Microbiome, Infection, and Nutrition

Formation of propionate and butyrate by the human colonic microbiota.

Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity.

Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice

Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations

Persistent microbiome alterations modulate the rate of post-dieting weight regain

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

Influence of early life exposure, host genetics and diet on the mouse gut microbiome and metabolome

Impact of the gut microbiota on enhancer accessibility in gut intraepithelial lymphocytes.

Universality of human microbial dynamics

Reparative inflammation takes charge of tissue regeneration

Intrinsic Defense Mechanisms of the Intestinal Epithelium

Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations

Gut Microbial Metabolites Fuel Host Antibody Responses

IFN-γ Hinders Recovery from Mucosal Inflammation during Antibiotic Therapy for Salmonella Gut Infection

Limited diversity sparks inflammation at the mucosal border

Rhythm and bugs: circadian clocks, gut microbiota, and enteric infections.

I’ll have a turkey and cheese sandwich

A microbial perspective of human developmental biology

The microbiome and innate immunity
The microbiota in adaptive immune homeostasis and disease

Interactions between the microbiota and pathogenic bacteria in the gut

Microbiome-wide association studies link dynamic microbial consortia to disease

Host-microbe interaction: Rules of the game for microbiota

The Host Shapes the Gut Microbiota via Fecal MicroRNA

Another Reason to Thank Mom: Gestational Effects of Microbiota Metabolites

Preterm infant gut microbiota affects intestinal epithelial development in a humanized microbiome gnotobiotic mouse model.

Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice

Host Selection of Microbiota via Differential Adhesion

Tummy Time: The Infant Microbiota–IgA Connection

Antibiotics, birth mode, and diet shape microbiome maturation during early life

Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes

Host-Protozoan Interactions Protect from Mucosal Infections through Activation of the Inflammasome

Adaptive immune response in symptomatic and asymptomatic enteric protozoal infection: evidence for a determining role of parasite genetic heterogeneity in host immunity to human giardiasis

The Liver at the Nexus of Host-Microbial Interactions

Modeling human enteric dysbiosis and rotavirus immunity in gnotobiotic pigs.

Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity

Culture of previously uncultured members of the human gut microbiota by culturomics